Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kai Wucherpfennig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Kai Wucherpfennig and Gordon Freeman.
Connection Strength

0.430
  1. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.
    View in: PubMed
    Score: 0.236
  2. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018 10; 24(10):1550-1558.
    View in: PubMed
    Score: 0.050
  3. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017 11 23; 8(1):1747.
    View in: PubMed
    Score: 0.047
  4. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58.
    View in: PubMed
    Score: 0.038
  5. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
    View in: PubMed
    Score: 0.035
  6. Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol. 2008 May; 82(10):5109-14.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.